APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glucagon Like Peptide-1 (GLP-1) Agonists

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Selected research

Industry Growth & Trends

Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Growth and Trends Forecast to 2032

25 December 202595 pages

Choose your research edition.

Industry ResearchGlucagon Like Peptide-1 (GLP-1) Agonists Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.

Read the full market overview

Report Scope

This report provides a structured, data-driven view of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Glucagon Like Peptide-1 (GLP-1) Agonists market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Glucagon Like Peptide-1 (GLP-1) Agonists market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Glucagon Like Peptide-1 (GLP-1) Agonists.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Glucagon Like Peptide-1 (GLP-1) Agonists market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Glucagon Like Peptide-1 (GLP-1) Agonists Market by Company

Novo Nordisk

AstraZeneca

Eli Lily

GSK

Sanofi

Bristol-Myers Squibb

Amylin

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application

Hospital

Pharmacy

Other

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucagon Like Peptide-1 (GLP-1) Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Like Peptide-1 (GLP-1) Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Exenatied Table 2. Major Company of Liraglutide Table 3. Major Company of Lixisenatide Table 4. Major Company of Albiglutide Table 5. Major Company of Dulaglutide Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type (2021-2026) Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (US$ Million) Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type (2021-2026) Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021-2026) & (USD/Unit) Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027-2032) & (K Units) Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type (2027-2032) Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027-2032) & (US$ Million) Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type (2027-2032) Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2027-2032) & (USD/Unit) Table 17. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 18. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 20. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 24. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (US$ Million) Table 27. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends Table 28. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers Table 29. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges Table 30. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company (2021-2026) Table 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2021-2026) & (K Units) Table 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Company (2021-2026) Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Price by Company (2021-2026) & (USD/Unit) Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Major Company Production Sites and Headquarters Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company, Product Type & Application Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021-2026) & (K Units) Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Region (2021-2026) Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021-2026) & (US$ Million) Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Region (2021-2026) Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 48. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2027-2032) & (K Units) Table 49. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Region (2027-2032) Table 50. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2027-2032) & (US$ Million) Table 51. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Region (2027-2032) Table 52. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2027-2032) Table 53. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 55. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application (2021-2026) Table 56. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (US$ Million) Table 57. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application (2021-2026) Table 58. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021-2026) & (USD/Unit) Table 59. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027-2032) & (K Units) Table 60. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application (2027-2032) Table 61. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027-2032) & (US$ Million) Table 62. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application (2027-2032) Table 63. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2027-2032) & (USD/Unit) Table 64. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 65. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 67. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 71. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (US$ Million) Table 74. Novo Nordisk Company Information Table 75. Novo Nordisk Business Overview Table 76. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 77. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 78. Novo Nordisk Recent Development Table 79. AstraZeneca Company Information Table 80. AstraZeneca Business Overview Table 81. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 82. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 83. AstraZeneca Recent Development Table 84. Eli Lily Company Information Table 85. Eli Lily Business Overview Table 86. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 87. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 88. Eli Lily Recent Development Table 89. GSK Company Information Table 90. GSK Business Overview Table 91. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 92. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 93. GSK Recent Development Table 94. Sanofi Company Information Table 95. Sanofi Business Overview Table 96. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 97. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 98. Sanofi Recent Development Table 99. Bristol-Myers Squibb Company Information Table 100. Bristol-Myers Squibb Business Overview Table 101. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 102. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 103. Bristol-Myers Squibb Recent Development Table 104. Amylin Company Information Table 105. Amylin Business Overview Table 106. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 107. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 108. Amylin Recent Development Table 109. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 110. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 111. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2026) Table 112. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2027-2032) & (K Units) Table 113. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Country (2027-2032) Table 114. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 115. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country (2021-2026) & (US$ Million) Table 116. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Country (2021-2026) Table 117. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 118. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Country (2027-2032) Table 119. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 120. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 121. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2026) Table 122. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2027-2032) & (K Units) Table 123. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Country (2027-2032) Table 124. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country (2021-2026) & (US$ Million) Table 126. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Country (2021-2026) Table 127. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Country (2027-2032) Table 129. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 130. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 131. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2026) Table 132. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2027-2032) & (K Units) Table 133. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Country (2027-2032) Table 134. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country (2021-2026) & (US$ Million) Table 136. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Country (2021-2026) Table 137. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Country (2027-2032) Table 139. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 140. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 141. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2026) Table 142. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2027-2032) & (K Units) Table 143. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Country (2027-2032) Table 144. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country (2021-2026) & (US$ Million) Table 146. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Country (2021-2026) Table 147. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Country (2027-2032) Table 149. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 150. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 151. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2026) Table 152. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2027-2032) & (K Units) Table 153. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Country (2027-2032) Table 154. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country (2021-2026) & (US$ Million) Table 156. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Country (2021-2026) Table 157. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Country (2027-2032) Table 159. Key Raw Materials Table 160. Raw Materials Key Suppliers Table 161. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List Table 162. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Image Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (2021-2032) & (US$ Million) Figure 4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2021-2032) & (K Units) Figure 5. Exenatied Image Figure 6. Global Exenatied Sales YoY Growth (2021-2032) & (K Units) Figure 7. Liraglutide Image Figure 8. Global Liraglutide Sales YoY Growth (2021-2032) & (K Units) Figure 9. Lixisenatide Image Figure 10. Global Lixisenatide Sales YoY Growth (2021-2032) & (K Units) Figure 11. Albiglutide Image Figure 12. Global Albiglutide Sales YoY Growth (2021-2032) & (K Units) Figure 13. Dulaglutide Image Figure 14. Global Dulaglutide Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Type 2025 VS 2032 Figure 17. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type in 2025 Figure 18. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type in 2025 Figure 19. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type in 2025 Figure 20. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type in 2025 Figure 23. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 31. Pharmacy Image Figure 32. Global Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 33. Other Image Figure 34. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Application 2025 VS 2032 Figure 37. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application in 2025 Figure 38. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application in 2025 Figure 39. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application in 2025 Figure 40. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application in 2025 Figure 43. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share in Value by Application in 2025 Figure 47. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Exenatied
  • Liraglutide
  • Lixisenatide
  • Albiglutide
  • Dulaglutide
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Novo Nordisk
  • AstraZeneca
  • Eli Lily
  • GSK
  • Sanofi
  • Bristol-Myers Squibb
  • Amylin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Type
  6. 1.3.1 Exenatied
  7. 1.3.2 Liraglutide
  8. 1.3.3 Lixisenatide
  9. 1.3.4 Albiglutide
  10. 1.3.5 Dulaglutide
  11. 1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
  12. 1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
  2. 2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
  3. 2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
  4. 2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2026)
  2. 3.2 Global Top Players by Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2021-2026)
  3. 3.3 Global Top Players by Glucagon Like Peptide-1 (GLP-1) Agonists Price (2021-2026)
  4. 3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Major Company Production Sites & Headquarters
  6. 3.6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company, Product Type & Application
  7. 3.7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Glucagon Like Peptide-1 (GLP-1) Agonists Tier 1, Tier 2, and Tier 3
4 Glucagon Like Peptide-1 (GLP-1) Agonists Regional Status and Outlook
  1. 4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Size by Region
  3. 4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecasted Market Size by Region
  7. 4.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Glucagon Like Peptide-1 (GLP-1) Agonists by Application
  1. 5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
  6. 5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novo Nordisk
  2. 6.1.1 Novo Nordisk Company Information
  3. 6.1.2 Novo Nordisk Business Overview
  4. 6.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  6. 6.1.5 Novo Nordisk Recent Developments
  7. 6.2 AstraZeneca
  8. 6.2.1 AstraZeneca Company Information
  9. 6.2.2 AstraZeneca Business Overview
  10. 6.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  12. 6.2.5 AstraZeneca Recent Developments
  13. 6.3 Eli Lily
  14. 6.3.1 Eli Lily Company Information
  15. 6.3.2 Eli Lily Business Overview
  16. 6.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  18. 6.3.5 Eli Lily Recent Developments
  19. 6.4 GSK
  20. 6.4.1 GSK Company Information
  21. 6.4.2 GSK Business Overview
  22. 6.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  24. 6.4.5 GSK Recent Developments
  25. 6.5 Sanofi
  26. 6.5.1 Sanofi Company Information
  27. 6.5.2 Sanofi Business Overview
  28. 6.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  30. 6.5.5 Sanofi Recent Developments
  31. 6.6 Bristol-Myers Squibb
  32. 6.6.1 Bristol-Myers Squibb Company Information
  33. 6.6.2 Bristol-Myers Squibb Business Overview
  34. 6.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  36. 6.6.5 Bristol-Myers Squibb Recent Developments
  37. 6.7 Amylin
  38. 6.7.1 Amylin Company Information
  39. 6.7.2 Amylin Business Overview
  40. 6.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  42. 6.7.5 Amylin Recent Developments
7 North America by Country
  1. 7.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
  2. 7.1.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026)
  4. 7.1.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2027-2032)
  5. 7.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
  6. 7.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country (2021-2026)
  8. 7.2.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
  2. 8.1.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026)
  4. 8.1.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
  6. 8.2.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country (2021-2026)
  8. 8.2.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
  2. 9.1.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
  6. 9.2.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
  2. 10.1.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026)
  4. 10.1.3 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2027-2032)
  5. 10.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
  6. 10.2.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country (2021-2026)
  8. 10.2.3 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country
  2. 11.1.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
  6. 11.2.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Analysis
  2. 12.1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process
  7. 12.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
  10. 12.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst